Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | ARID1B |
Variant | Q123* |
Impact List | nonsense |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | ARID1B Q123* results in a premature truncation of the Arid1b protein at amino acid 123 of 2236 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), Q123* is predicted to lead to a loss of Arid1b protein function. |
Associated Drug Resistance | |
Category Variants Paths |
ARID1B mutant ARID1B inact mut ARID1B Q123* |
Transcript | NM_017519.2 |
gDNA | chr6:g.156778296C>T |
cDNA | c.367C>T |
Protein | p.Q123* |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_017011103.2 | chr6:g.156778296C>T | c.367C>T | p.Q123* | RefSeq | GRCh38/hg38 |
XM_017011105.2 | chr6:g.156778296C>T | c.367C>T | p.Q123* | RefSeq | GRCh38/hg38 |
XM_011535984 | chr6:g.156778296C>T | c.367C>T | p.Q123* | RefSeq | GRCh38/hg38 |
NM_017519 | chr6:g.156778296C>T | c.367C>T | p.Q123* | RefSeq | GRCh38/hg38 |
NM_020732.3 | chr6:g.156778296C>T | c.367C>T | p.Q123* | RefSeq | GRCh38/hg38 |
XM_017011107.2 | chr6:g.156778296C>T | c.367C>T | p.Q123* | RefSeq | GRCh38/hg38 |
XM_017011105 | chr6:g.156778296C>T | c.367C>T | p.Q123* | RefSeq | GRCh38/hg38 |
XM_017011107 | chr6:g.156778296C>T | c.367C>T | p.Q123* | RefSeq | GRCh38/hg38 |
XM_017011104.1 | chr6:g.156778296C>T | c.367C>T | p.Q123* | RefSeq | GRCh38/hg38 |
XM_005267069 | chr6:g.156778296C>T | c.367C>T | p.Q123* | RefSeq | GRCh38/hg38 |
NM_017519.2 | chr6:g.156778296C>T | c.367C>T | p.Q123* | RefSeq | GRCh38/hg38 |
XM_017011106.2 | chr6:g.156778296C>T | c.367C>T | p.Q123* | RefSeq | GRCh38/hg38 |
XM_017011103 | chr6:g.156778296C>T | c.367C>T | p.Q123* | RefSeq | GRCh38/hg38 |
NM_001346813.1 | chr6:g.156778296C>T | c.367C>T | p.Q123* | RefSeq | GRCh38/hg38 |
XM_017011106 | chr6:g.156778296C>T | c.367C>T | p.Q123* | RefSeq | GRCh38/hg38 |
XM_017011104 | chr6:g.156778296C>T | c.367C>T | p.Q123* | RefSeq | GRCh38/hg38 |
NM_020732 | chr6:g.156778296C>T | c.367C>T | p.Q123* | RefSeq | GRCh38/hg38 |
XM_011535984.2 | chr6:g.156778296C>T | c.367C>T | p.Q123* | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ARID1B inact mut | gastroesophageal adenocarcinoma | not predictive | unspecified immune checkpoint inhibitor | Clinical Study - Cohort | Actionable | In a retrospective analysis, somatic loss-of-function mutations in the genes of the mSWI/SNF complex, including ARID1B, did not correlate with improved survival in 2 separate cohorts of patients with gastroesophageal adenocarcinoma treated with systemic immune checkpoint inhibitors, with adjusted HRs for overall survival of 0.70 (p=0.403, n=66) and 0.46 (p=0.071, n=59), respectively (PMID: 32321774). | 32321774 |
ARID1B inact mut | colorectal adenocarcinoma | unknown | unspecified immune checkpoint inhibitor | Clinical Study - Cohort | Actionable | In a retrospective analysis, somatic loss-of-function mutations in the genes of the mSWI/SNF complex, including ARID1B, correlated with improved survival in one cohort of patients with colorectal adenocarcinoma treated with systemic immune checkpoint inhibitors but not the other, with adjusted HRs for overall survival of 0.30 (p=0.03, n=35) and 0.56 (p=0.244, n=63), respectively (PMID: 32321774). | 32321774 |
ARID1B inact mut | melanoma | not predictive | unspecified immune checkpoint inhibitor | Clinical Study - Cohort | Actionable | In a retrospective analysis, somatic loss-of-function mutations in the genes of the mSWI/SNF complex, including ARID1B, did not correlate with improved survival in 2 separate cohorts of patients with melanoma treated with systemic immune checkpoint inhibitors, with adjusted HRs for overall survival of 1.70 (p=0.192, n=86) and 1.02 (p=0.939, n=192), respectively (PMID: 32321774). | 32321774 |
ARID1B inact mut | transitional cell carcinoma | not predictive | unspecified immune checkpoint inhibitor | Clinical Study - Cohort | Actionable | In a retrospective analysis, somatic loss-of-function mutations in the genes of the mSWI/SNF complex, including ARID1B, did not correlate with improved survival in 2 separate cohorts of patients with transitional cell carcinoma treated with systemic immune checkpoint inhibitors, with adjusted HRs for overall survival of 1.44 (p=0.34, n=56) and 0.82 (p=0.559, n=93), respectively (PMID: 32321774). | 32321774 |
ARID1B inact mut | head and neck squamous cell carcinoma | not predictive | unspecified immune checkpoint inhibitor | Clinical Study - Cohort | Actionable | In a retrospective analysis, somatic loss-of-function mutations in the genes of the mSWI/SNF complex, including ARID1B, did not correlate with improved survival in 2 separate cohorts of patients with head and neck squamous cell carcinoma treated with systemic immune checkpoint inhibitors, with adjusted HRs for overall survival of 0.74 (p=0.631, n=31) and 0.76 (p=0.622, n=68), respectively (PMID: 32321774). | 32321774 |